Prolonged Secondary Stroke Prevention with Edoxaban: A Long-Term Follow-Up of the SATES Study.
DOACs
NOACs
NVAF
anticoagulants
atrial fibrillation
cardioembolism
edoxaban
stroke
Journal
Brain sciences
ISSN: 2076-3425
Titre abrégé: Brain Sci
Pays: Switzerland
ID NLM: 101598646
Informations de publication
Date de publication:
02 Nov 2023
02 Nov 2023
Historique:
received:
25
09
2023
revised:
30
10
2023
accepted:
31
10
2023
medline:
25
11
2023
pubmed:
25
11
2023
entrez:
25
11
2023
Statut:
epublish
Résumé
Little evidence is available on the long-term efficacy and safety of edoxaban, mainly due to the recent release date. The primary objective of the study was to evaluate the safety of edoxaban, defined by the incidence of major bleedings. We then aimed to evaluate the incidence of thromboembolic events and the persistence of edoxaban therapy in the long-term. In this observational cohort study, we included ischemic stroke patients enrolled in a previous study to evaluate the safety and efficacy of long-term edoxaban treatment. Data were collected by a trained investigator through a structured telephone interview. Sixty-three subjects (median age 81.0 (73.5-88.0) years, 38.1% male) were included in the study, with a mean follow-up of 4.4 ± 0.7 years (range: 3.2-5.5 years). Only one patient (1.6%, 0.4%/year) presented a major extracranial bleeding, and none had cerebral hemorrhage. Six thromboembolic events occurred in five patients (7.9%): three recurrent strokes, two transient ischemic attacks, and one myocardial infarction (2.2%/year). Over a follow-up period of more than three years, 13 patients discontinued edoxaban (20.6%).
Sections du résumé
BACKGROUND
BACKGROUND
Little evidence is available on the long-term efficacy and safety of edoxaban, mainly due to the recent release date. The primary objective of the study was to evaluate the safety of edoxaban, defined by the incidence of major bleedings. We then aimed to evaluate the incidence of thromboembolic events and the persistence of edoxaban therapy in the long-term.
METHODS
METHODS
In this observational cohort study, we included ischemic stroke patients enrolled in a previous study to evaluate the safety and efficacy of long-term edoxaban treatment. Data were collected by a trained investigator through a structured telephone interview.
RESULTS
RESULTS
Sixty-three subjects (median age 81.0 (73.5-88.0) years, 38.1% male) were included in the study, with a mean follow-up of 4.4 ± 0.7 years (range: 3.2-5.5 years). Only one patient (1.6%, 0.4%/year) presented a major extracranial bleeding, and none had cerebral hemorrhage. Six thromboembolic events occurred in five patients (7.9%): three recurrent strokes, two transient ischemic attacks, and one myocardial infarction (2.2%/year). Over a follow-up period of more than three years, 13 patients discontinued edoxaban (20.6%).
Identifiants
pubmed: 38002501
pii: brainsci13111541
doi: 10.3390/brainsci13111541
pmc: PMC10669805
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Circulation. 2022 Jan 25;145(4):242-255
pubmed: 34985309
J Am Coll Cardiol. 2018 Aug 21;72(8):838-853
pubmed: 30115222
J Clin Pharmacol. 2023 Jun;63(6):654-663
pubmed: 36609916
Trends Cardiovasc Med. 2023 Jan;33(1):23-29
pubmed: 34890796
Chest. 2010 Nov;138(5):1093-100
pubmed: 20299623
Lancet. 2000 May 13;355(9216):1670-4
pubmed: 10905241
Chest. 2010 Feb;137(2):263-72
pubmed: 19762550
Stroke. 1993 Jan;24(1):35-41
pubmed: 7678184
Stroke. 2008 Sep;39(9):2485-90
pubmed: 18617663
J Thromb Haemost. 2005 Apr;3(4):692-4
pubmed: 15842354
Stroke Vasc Neurol. 2018 Mar 9;3(2):76-83
pubmed: 30022801
J Am Heart Assoc. 2018 Mar 10;7(6):
pubmed: 29525778
Circ Res. 2017 Feb 3;120(3):439-448
pubmed: 28154096
Br J Clin Pharmacol. 2019 Sep;85(9):2134-2142
pubmed: 31218738
J Clin Med. 2021 Feb 03;10(4):
pubmed: 33546442
Br J Clin Pharmacol. 2020 Aug;86(8):1567-1574
pubmed: 32090369
Lancet. 2015 Jul 11;386(9989):154-62
pubmed: 25960110
J Am Heart Assoc. 2016 May 20;5(5):
pubmed: 27207971
Brain Sci. 2020 Dec 30;11(1):
pubmed: 33396700
J Neurol. 2022 Jan;269(1):470-480
pubmed: 34718884
N Engl J Med. 2013 Nov 28;369(22):2093-104
pubmed: 24251359
Eur Heart J. 2014 Jul 21;35(28):1864-72
pubmed: 24561548
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
Int J Cardiol. 2021 Jun 15;333:162-166
pubmed: 33705844
J Am Coll Cardiol. 2016 Dec 20;68(24):2597-2604
pubmed: 27978942
Front Cardiovasc Med. 2022 Sep 29;9:994085
pubmed: 36247477
Front Pharmacol. 2023 Feb 02;14:1125576
pubmed: 36817122